AU · rank #8 · 2026-07-23
MGTX
NASDAQ · $1.16B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.258 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.197 |
| Analyst upside Consensus target $28.38 | +133.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +20.94% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.60 |
| Gross margin TTM | +95.4% |
| 52w high | $15.35 |
| Market cap (USD) | $1.16B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
MeiraGTx is a clinical-stage biotechnology company developing targeted gene therapies for salivary gland, ophthalmology, and neurodegenerative disorders, supported by an in-house manufacturing platform.
Rationale
The screened 133.3% analyst upside and 100% positive revision agreement are highly credible given the massive, non-dilutive $400 million Oberland Capital financing and the near-term regulatory filings for its Phase 3-ready XLRP program.
Material risks
- 1Severe asset concentration in three key pipeline programs (bota-vec, AAV-AQP1, and AAV-AIPL1) where any clinical, manufacturing, or FDA regulatory failure would drastically impair the company's valuation.
- 2Significant debt refinancing and royalty payment pressure under the senior secured Oberland notes and Perceptive Credit agreement maturing in May 2027 if commercial launches are delayed.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.